Highly selective and sensitive potentiometric determination of favipiravir in COVID-19 antiviral drug formulations

被引:1
|
作者
Topcu, Cihan [1 ]
Aydin, Senanur [1 ]
Atasoy, Betul Hilal [1 ]
Yilmaz, Rabia Rana [1 ]
Coldur, Fatih [2 ]
Caglar, Bulent [3 ]
机构
[1] Samsun Univ, Fac Engn & Nat Sci, Dept Biomed Engn, Samsun, Turkiye
[2] Erzincan Binali Yildirim Univ, Fac Arts & Sci, Dept Chem, Erzincan, Turkiye
[3] Ondokuz Mayis Univ, Dept Food Feed & Med, Inst Hemp Res, Samsun, Turkiye
关键词
COVID-19; Favipiravir; Electrochemical favipiravir sensor; Potentiometry; ELECTRODE; CONSTRUCTION; COPPER(II); SENSOR; IONS;
D O I
10.1016/j.microc.2024.111390
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
In this study, a novel all-solid-state electrochemical sensor based on favipiravir-tetraphenylborate (FAV-TPB) electroactive material was developed and reported for FAV's highly selective and sensitive potentiometric determination in COVID-19 antiviral drug formulations. All-solid-state FAV selective sensor was fabricated by mixing and properly pressing FAV-TPB, graphite (G), multi-walled carbon nanotube (MWCNT), and paraffin oil (PO). In order to obtain the best sensor response, the sensor component ratios were optimized. The most satisfying response characteristics was obtained with the sensor composition FAV-TPB:G:MWCNT:PO in the ratio 32.5:42.5:5:20 (w/w %). The developed sensor displayed a wide linear near-Nernstian response to FAV over the concentration of 1.0 x 10-6 - 1.0 x 10- 1 molL- 1 with a slope of 53.6 +/- 1.4 mV (R2 = 0.9997). The detection limits of the sensor was calculated as 6.0 x 10- 7molL- 1, respectively. The dynamic response time of the sensor was 7 s, and the sensor exhibited fairly reproducible potentiometric responses. In the pH range of 6.0-8.0, the sensor's potential response was not affected by the pH change of the test solutions. The improved sensor had a wide temperature tolerance, and its response remained unchanged in the 10-40 degree celsius temperature range. The interference effect of some chemical and biological species was evaluated by the matched potential method and separate solution method. The sensor worked stable for 12 weeks without any considerable change in its potential response. The analytical applications of the sensor were successfully carried out with the potentiometric titration of FAV with sodium tetraphenylborate solution and also the direct determination of favipiravir in COVID-19 antiviral drug formulations.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
    Dauby, Nicolas
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (03) : E847 - E848
  • [32] Evaluation of the effect of favipiravir on patients with COVID-19
    Kamali, Alireza
    Sarmadian, Hossein
    Mahmoodiyeh, Behnam
    Valibeik, Shamim
    Farmani, Farzane
    Bashirgonbadi, Zahra
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2023, 12 (02) : 242 - 245
  • [33] Fujifilm tests favipiravir as COVID-19 treatment
    Matsuoka, Katsumori
    CHEMICAL & ENGINEERING NEWS, 2020, 98 (15) : 11 - 11
  • [34] Pharmacokinetic characterization of favipiravir in patients with COVID-19
    Gulhan, Rezzan
    Eryuksel, Emel
    Oglu, Medine Gulcebi Idriz
    Culpan, Yekta
    Toplu, Aylin
    Kocakaya, Derya
    Tigen, Elif
    Sengel, Buket Erturk
    Sili, Uluhan
    Yildizeli, Sehnaz Olgun
    Balcan, Mehmet Baran
    Elci, Abdullah
    Bulut, Cenk
    Karaalp, Atila
    Yananli, Hasan Raci
    Guner, Abdullah Emre
    Hatipoglu, Mustafa
    Karakurt, Sait
    Korten, Volkan
    Ratnaraj, Neville
    Patsalos, Philip
    Ay, Pinar
    Onat, Filiz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3516 - 3522
  • [35] Future of antivirals in COVID-19: The case of favipiravir
    Kow, Chia Siang
    Ramachandram, Dinesh Sangarran
    Hasan, Syed Shahzad
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 103
  • [36] Population pharmacokinetics of favipiravir in patients with COVID-19
    Irie, Kei
    Nakagawa, Atsushi
    Fujita, Hirotoshi
    Tamura, Ryo
    Eto, Masaaki
    Ikesue, Hiroaki
    Muroi, Nobuyuki
    Fukushima, Shoji
    Tomii, Keisuke
    Hashida, Tohru
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (10): : 1161 - 1170
  • [37] Favipiravir: A Possible Pharmaceutical Treatment for COVID-19
    Yanai, Hidekatsu
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 10 (02) : 33 - 34
  • [38] Use of Favipiravir in Lactating Mother With COVID-19
    Karabayir, Nalan
    Dogan, Ozlem Ocal
    Canbeyli, Gulcin
    TURKISH ARCHIVES OF PEDIATRICS, 2021, 56 (05): : 533 - 534
  • [39] Hematological Malignancy Patients, COVID-19, and Favipiravir
    Mungmunpuntipantip, Rujittika
    Wiwanitkit, Viroj
    TURKISH JOURNAL OF HEMATOLOGY, 2021, 38 (04) : 331 - 332
  • [40] An Innovative Polymer-Based Electrochemical Sensor Encrusted with Tb Nanoparticles for the Detection of Favipiravir: A Potential Antiviral Drug for the Treatment of COVID-19
    Ali, Marwa F. B.
    Saraya, Roshdy E.
    El Deeb, Sami
    Ibrahim, Adel Ehab
    Salman, Baher I.
    BIOSENSORS-BASEL, 2023, 13 (02):